DNA Methylation and Vascular Function
University of Illinois at Chicago · with National Heart, Lung, and Blood Institute (NHLBI) · NCT03527420
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–50 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 80
- US sites recruiting
- 1
- Study start
- October 11, 2019
- Record last updated
- September 15, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The main objective is to examine DNA hypomethylation as an underlying mechanism for the increased production of inflammatory cytokines and the impaired vascular function in obese individuals and as a potential target for nonpharmacological preventive/therapeutic interventions such as aerobic exercise.
Being studied: Exercise training
Conditions: Obesity; Vascular Dysfunction
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- BMI ≥ 35 kg/m2
- Between ages 18-50 years
- Not pregnant
- Approved for a bariatric surgery
Exclusion Criteria
- To avoid confounding from other inflammatory conditions individuals with current cancer, heart, kidney or liver disease, gallbladder disease or acute or chronic inflammatory diseases (including rheumatoid arthritis, lupus and other autoimmune diseases and genetic diseases) will be excluded
- Pregnant women will be excluded, as they will not be eligible for bariatric surgery
- Current smokers
- Currently abusing alcohol or drugs
Recruiting US locations
University of Illinois at Chicago
Chicago, IL 60612
Site contact: Abeer M Mohamed, MD, PhD · 312-355-8099 · amahmo4@uic.edu
Study contacts (from the official record)
- Abeer Mohamed, MD, PhD · 3127539998 · amahmo4@uic.edu
Similar studies in Illinois
All weight loss studies in Illinois →- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Skokie, IL + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Chicago, IL + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Champaign, IL + 19 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
Boston Scientific Corporation
- Location
- Chicago, IL + 8 other US sites
- Eligibility basics
- Ages 18+